Flavoquine®, Camoquin® Suspension + Flavoquine®, Camoquin® Suspension
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Falciparum Malaria
Conditions
Falciparum Malaria
Trial Timeline
May 1, 2009 → Jun 1, 2009
NCT ID
NCT00859807About Flavoquine®, Camoquin® Suspension + Flavoquine®, Camoquin® Suspension
Flavoquine®, Camoquin® Suspension + Flavoquine®, Camoquin® Suspension is a approved stage product being developed by Pfizer for Falciparum Malaria. The current trial status is completed. This product is registered under clinical trial identifier NCT00859807. Target conditions include Falciparum Malaria.
What happened to similar drugs?
2 of 4 similar drugs in Falciparum Malaria were approved
Approved (2) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00859807 | Approved | Completed |
Competing Products
20 competing products in Falciparum Malaria